Skip to main content

Table 7 Health technology assessment information deemed to be important by stakeholders by stakeholder category (scale responses: 1 = strongly disagree; 7 = strongly agree)

From: Similarities and differences between stakeholders’ opinions on using Health Technology Assessment (HTA) information across five European countries: results from the EQUIPT survey

 

Decision-maker

Purchaser of services/pharma products

Professional service provider

Evidence generator

Advocate of health promotion

Total

Kruskal–Wallis test

Statements

n

Mean (SD)

n

Mean (SD)

n

Mean (SD)

n

Mean (SD)

n

Mean (SD)

n

Mean (SD)

P value

Prevalence of smoking

29

5.66 (2.01)

7

6.71 (0.49)

18

6.33 (1.28)

25

5.84 (1.72)

14

5.57 (1.70)

93

5.90 (1.69)

0.43

Costs of smoking

29

6.55 (0.83)

7

6.71 (0.76)

18

6.61 (0.78)

25

6.36 (1.32)

14

6.50 (0.65)

93

6.52 (0.94)

0.81

Quality of life

29

6.17 (0.85)

7

6.14 (1.22)

18

5.61 (1.58)

25

5.64 (1.66)

14

5.64 (1.69)

93

5.84 (1.40)

0.76

Mortality due to smoking

29

6.59 (0.98)

7

6.57 (0.79)

18

6.33 (1.03)

25

6.20 (1.50)

14

5.71 (2.09)

93

6.30 (1.35)

0.68

Effectiveness of smoking cessation interventions (such as quit and relapse rates)

29

6.59 (0.83)

7

6.71 (0.76)

18

6.56 (1.20)

25

6.12 (1.76)

14

6.29 (1.59)

93

6.42 (1.31)

0.76

Cost-effectiveness data comparing the cost of smoking cessation interventions with its health and wider benefits

29

6.66 (0.48)

7

6.86 (0.38)

18

6.33 (0.97)

25

6.52 (0.82)

14

6.57 (0.85)

93

6.56 (0.74)

0.65

Budget impact reflecting financial outcomes specifically at organisational level

29

6.17 (1.39)

7

6.57 (0.56)

18

6.33 (0.97)

25

6.20 (1.19)

14

6.36 (0.93)

93

6.27 (1.13)

0.99

  1. SD, Standard deviation